## Contents

### MINIREVIEW

Idiosyncratic Drug-Induced Liver Injury: Is Drug-Cytokine Interaction the Linchpin?

*Robert A. Roth, Ashley R. Maiuri, and Patricia E. Ganey*

Page 368

### BEHAVIORAL PHARMACOLOGY

- Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats
  
  *Vanessa Minervini, Sujata Dahal, and Charles P. France*

  Page 280

### CARDIOVASCULAR

- Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
  
  *Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Dean F. Rigal, Randy L. Webb, David Feldman, Fumin Fu, Michael Beil, Liang Jin, Donald R. Stanski, and Meindert Danhof*

  Page 356

### CELLULAR AND MOLECULAR

- Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
  
  *Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann, and Klaus Mohr*

  Page 289

- Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
  
  *Terry Petrou, Hervør L. Olsen, Christopher Thrasivoulou, John R. Masters, Jonathan F. Ashmore, and Aamir Ahmed*

  Page 378

### DRUG DISCOVERY AND TRANSLATIONAL MEDICINE

- Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease
  
  *Jeffrey Peng, Jill Dalton, Mark Butt, Kristin Tracy, Derek Kennedy, Peter Haroldsen, Rhea Cahayag, Stephen Zoog, Charles A. O’Neill, and Laurie S. Tsuruda*

  Page 313

- Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
  

  Page 346

### GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

- Effects of Antihypertensive Agents on Intestinal Contractility in the Spontaneously Hypertensive Rat: Angiotensin Receptor System Downregulation by Losartan
  
  *Glen Stephen Patten and Mahinda Yapa Abeywardena*

  Page 260

- Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
  
  *Robert J. Aiello, Patricia-Ann Bourassa, Qing Zhang, Jeffrey Dubins, Daniel R. Goldberg, Stéphane De Lombaert, Marc Humbert, Christophe Gaugnabert, Maria A. Cavasin, Timothy A. McKinsey, and Vishwas Paralkar*

  Page 267
INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
Soumita De, Alak Manna, Sunanda Kundu, Sritama De Sarkar, Uttara Chatterjee, Tuhinadri Sen, Subrata Chattopadhyay, and Mitali Chatterjee

GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton, and Mark A. Giembycz

NEUROPHARMACOLOGY

Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists
Amey Dhopeshwarkar, Natalia Murataeva, Alex Makriyannis, Alex Straiker, and Ken Mackie

LETTERS TO THE EDITOR

The Glutamate Model of Schizophrenia: It’s All About Signal Muscarinic Connections
Costa Vakalopoulos

Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1
Hong Shen, Wenying Li, W. Griffith Humphreys, and Yurong Lai

RESPONSE LETTERS

Response to “Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1”
Gerard Minuesa, Christopher Albert, Marçal Pastor-Anglada, Javier Martinez-Picado, and Hermann Koepsell

ERRATUM

Correction to: “Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy.”

Supplemental material is available at jpet.aspetjournals.org.

About the cover: Cell death signaling in IDILI drug-cytokine interaction. See the article by Roth et al. (dx.doi.org/10.1124/jpet.116.237578).